研究等業績 - その他 - 奥田 佑道
-
胸壁原発Ewing肉腫の1例
熊谷 奈保, 滝田 友里, 泉谷 有可, 坂本 祥, 長谷川 幸保, 浅野 真理子, 奥田 佑道, 竹田 正秀, 佐野 正明, 佐藤 一洋, 中山 勝敏, 高嶋 祉之具, 今井 一博, 南谷 佳弘, 南條 博
肺癌 ( (NPO)日本肺癌学会 ) 60 ( 7 ) 1032 - 1032 2020年12月
-
Yokota H.
Journal of Clinical Pharmacy and Therapeutics ( Journal of Clinical Pharmacy and Therapeutics ) 45 ( 4 ) 652 - 659 2020年08月
WHAT IS KNOWN AND OBJECTIVE: We investigated the correlations among signal transducer and activator of transcription 3 (STAT3) rs4796793C >G polymorphism, gefitinib pharmacokinetics and clinical responses in Japanese patients with non-small cell lung cancer receiving gefitinib therapy. METHODS: Forty-five patients were enrolled in this study. Plasma trough concentrations (C0 ) of gefitinib at the steady-state were measured by high-performance liquid chromatography. RESULTS AND DISCUSSION: Patients having a gefitinib C0 of at least ≥200 ng/mL had significantly longer PFS than patients having a C0 of <200 ng/mL (median [95% confidence interval (CI)] PFS: 11.0 [8.2-13.7] and 5.3 [0.0-12.0] months, respectively, P = .042). There were no significant differences in PFS between patients with STAT3 rs4796793C/C and G alleles; however, patients with STAT3 rs4796793C/C having a gefitinib C0 of ≥ 200 ng/mL had significantly longer progression-free survival (PFS) and overall survival (OS) than those with a C0 of <200 ng/mL (median [95% CI] PFS: 11.4 [4.1-18.6] and 3.0 [0.0-7.0] months, respectively, P = .008; median [95% CI] OS: 20.6 [7.4-33.7] and 12.6 [10.1-15.1] months, respectively, P = .042). In patients with the STAT3 rs4796793G allele, there were no significant differences in PFS and OS between the two gefitinib C0 groups. In addition, there were no significant differences in PFS or OS according to smoking, presence of proton pump inhibitor combination, or onset of side effects. WHAT IS NEW AND CONCLUSION: Clinical outcomes of gefitinib in patients with the STAT3 rs4796793C/C genotype depended on plasma concentrations of gefitinib. In addition to information regarding EGFR mutations, the STAT3 rs4796793C >G polymorphism and gefitinib C0 may be potential predictors of clinical outcomes after beginning of gefitinib therapy.
-
慢性好酸球性肺炎(CEP)患者のBALFに観察された好酸球ETosis
竹田 正秀, 坂本 祥, 佐藤 一洋, 植木 重治, 宮部 結, 佐野 正明, 奥田 佑道, 浅野 真理子, 長谷川 幸保, 熊谷 奈保, 廣川 誠, 中山 勝敏
日本呼吸器学会誌 ( (一社)日本呼吸器学会 ) 9 ( 増刊 ) 226 - 226 2020年08月
-
サルコイドーシス様の臨床像を呈したBCG膀胱内注入療法による播種性Mycobacterium bovis感染症の1例
長谷川幸保, 滝田友里, 泉谷有可, 熊谷奈保, 須藤和久, 坂本祥, 奥田佑道, 浅野真理子, 竹田正秀, 佐藤一洋, 中山勝敏, 三浦一樹
日本サルコイドーシス/肉芽腫性疾患学会雑誌 40 ( 1-2 ) 2020年
-
再検討で混合型小細胞癌と診断されたEGFR陽性肺腺癌の1例
滝田友里, 奥田佑道, 坂本祥, 泉谷有可, 熊谷奈保, 長谷川幸保, 浅野真理子, 竹田正秀, 佐野正明, 佐藤一洋, 中山勝敏, 廣嶋優子, 南條博
肺癌(Web) 60 ( 7 ) 2020年
-
再生検でALK遺伝子転座陽性となったEGFR遺伝子変異陽性肺腺癌の一例
奥田佑道, 佐藤一洋, 熊谷奈保, 坂本祥, 長谷川幸保, 浅野真理子, 竹田正秀, 中山勝敏
気管支学 42 2020年
-
慢性好酸球性肺炎(CEP)患者のBALFに観察された好酸球ETosis
竹田正秀, 坂本祥, 佐藤一洋, 植木重治, 宮部結, 佐野正明, 奥田佑道, 浅野真理子, 長谷川幸保, 熊谷奈保, 廣川誠, 中山勝敏
日本呼吸器学会誌(Web) 9 2020年
-
気管原発小細胞癌の一例
坂本祥, 坂本祥, 佐藤一洋, 旭ルリ子, 滝田友里, 泉谷有可, 長谷川幸保, 金田浩人, 浅野真理子, 奥田佑道, 竹田正秀, 杉山直幸, 中山勝敏
気管支学 42 2020年
-
胸壁原発Ewing肉腫の1例
熊谷奈保, 滝田友里, 泉谷有可, 坂本祥, 長谷川幸保, 浅野真理子, 奥田佑道, 竹田正秀, 佐野正明, 佐藤一洋, 中山勝敏, 高嶋祉之具, 今井一博, 南谷佳弘, 南條博
肺癌(Web) 60 ( 7 ) 2020年
-
Takeda M.
Journal of Medical Case Reports ( Journal of Medical Case Reports ) 13 ( 1 ) 118 - 118 2019年04月
BACKGROUND: Anaplastic lymphoma kinase-positive lung cancer is a form of lung cancer that accounts for approximately 5% of non-small cell lung cancers. Recently, anaplastic lymphoma kinase inhibitors have been used for treatment of anaplastic lymphoma kinase-positive lung cancer, and their high clinical effect has also been demonstrated in cases of advanced stage lung cancer. Alectinib is an anaplastic lymphoma kinase inhibitor that it is recognized as a standard drug for primary therapy because of its superiority to crizotinib. CASE PRESENTATION: A 37-year-old Japanese man was admitted to our hospital due to multiple brain metastases. An autopsy report revealed that the cause of death was anaplastic lymphoma kinase-positive lung cancer, exacerbated in a short period despite treatment with alectinib. Necropsy revealed anaplastic lymphoma kinase-positive adenosquamous carcinoma of the lung, suggesting that it was involved in the prognosis of this patient. Based on the autopsy results, we reviewed the pathological tissue from transbronchial lung biopsy at the time of clinical diagnosis. The tissue specimen for clinical diagnosis in this case was a papillary adenocarcinoma. However, when this tissue was immunostained, thyroid transcription factor 1-negative and cytokeratin 5/6-positive parts were recognized. This result indicates that we could diagnose this patient as having had adenosquamous carcinoma of the lung. CONCLUSION: In cases of anaplastic lymphoma kinase-positive lung cancer poorly responsive to anaplastic lymphoma kinase inhibitors, re-examination of the tissue should be considered because there is a possibility of anaplastic lymphoma kinase-positive adenosquamous carcinoma.
-
気道上皮細胞からのサイトカイン産生,粘液産生におけるPhosphoinositide 3-kinaseγの関わり
竹田 正秀, 佐藤 一洋, 植木 重治, 丹 典子, 泉谷 有可, 熊谷 奈保, 坂本 祥, 須藤 和久, 長谷川 幸保, 浅野 真理子, 奥田 佑道, 佐野 正明, 中山 勝敏
日本呼吸器学会誌 ( (一社)日本呼吸器学会 ) 8 ( 増刊 ) 250 - 250 2019年03月
-
Blepharoptosis due to sarcoidosis-induced horner syndrome
Takeda M.
American Journal of Respiratory and Critical Care Medicine ( American Journal of Respiratory and Critical Care Medicine ) 200 ( 1 ) 101 - 102 2019年
-
COPD・喘息における術後肺合併症のリスク因子の検討
中山勝敏, 沼田尊功, 浅野真理子, 奥田佑道, 荒屋潤, 板倉有紀, 大田秀隆, 桑野和善
日本老年医学会雑誌 56 2019年
-
gefitinibの薬物動態と血中濃度の変動に関する検討
中山勝敏, 坂本祥, 佐藤一洋, 奥田佑道, 浅野真理子, 板倉有紀, 大田秀隆, 横田隼人, 赤嶺由美子, 三浦昌朋
日本老年医学会雑誌 56 2019年
-
ゲフィチニブの治療効果におけるSTAT3遺伝子多型と体内曝露量の影響
横田隼人, 佐藤一洋, 坂本祥, 奥田佑道, 中山勝敏, 三浦昌朋
日本医療薬学会年会講演要旨集(Web) 29 2019年
-
化学療法継続のため血小板輸血に難渋した高齢者小細胞肺癌の1例
浅野真理子, 佐藤一洋, 熊谷奈保, 坂本祥, 須藤和久, 奥田佑道, 竹田正秀, 佐野正明, 大田秀隆, 中山勝敏
日本老年医学会雑誌 56 ( 4 ) 2019年
-
気道上皮細胞からのサイトカイン産生,粘液産生におけるPhosphoinositide 3-kinase γの関わり
竹田正秀, 佐藤一洋, 植木重治, 丹典子, 泉谷有可, 熊谷奈保, 坂本祥, 須藤和久, 長谷川幸保, 浅野真理子, 奥田佑道, 佐野正明, 中山勝敏
日本呼吸器学会誌(Web) 8 2019年
-
胸郭形成術後の呼吸機能障害に対しNPPVを長期使用した高齢患者の1例
奥田佑道, 佐藤一洋, 浅野真理子, 泉谷有可, 坂本祥, 須藤和久, 竹田正秀, 佐野正明, 大田秀隆, 中山勝敏
日本老年医学会雑誌 56 ( 4 ) 2019年